News

Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside

Cantor initiated coverage on Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company with five commercialized products. The company also collaborates with pharmaceutical companies to bring new molecules to market using its technologies, like PharmFilm. Aquestive is advancing a late-stage proprietary product candidate for severe allergic reactions, including anaphylaxis, and an earlier-stage epinephrine prodrug topical gel for various dermatology conditions. Cantor highlights that th

International, domestic insurers push into catastrophe-hit US property markets

LONDON (Reuters) -International and domestic insurers are pushing into the U.S. market for hard-to-protect homes, charging high premiums and enjoying strong profits after some U.S. firms pulled out. This has left greater room for non-domestic players like Hiscox and Munich Re to enter the fray, industry sources say. Recent large U.S. hurricanes Helene and Milton have added to concern about property losses.

MicroStrategy's Nasdaq-100 entry attracts nearly $11 million of retail inflows

Retail investors poured nearly $11 million into MicroStrategy's shares on Monday, almost three times their average daily inflows this year, after the biggest corporate holder of bitcoin secured a spot in the Nasdaq-100 index. The data, compiled by Vanda Research on Tuesday, highlights the bitcoin bull's growing popularity among individual investors after its stock notched an eye-popping return of nearly 550%, outpacing Wall Street favorite Nvidia's roughly 160% surge so far in 2024. Promoted as a financial tool free of government intermediaries, bitcoin often earns its corporate champions a devoted following.